Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease – Unmet Need – Unmet Need – Early Alzheimer’s Disease (US/EU)

Login to access report north_east
Contact sales account_box

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-related safety risks. Emerging DMTs with near-term launch potential (e.g., subcutaneous lecanemab, Eli Lilly’s remternetug, Roche’s trontinemab, Novo Nordisk’s semaglutide) may deliver greater biomarker and/or clinical efficacy, lower ARIA risk, or improved delivery profiles. This report examines the influence of a key clinical (e.g., reduction of cognitive and functional decline, plaque clearance, ARIA risk) and nonclinical (i.e., out-of-pocket cost) attributes on neurologists’ prescribing decisions and assesses the key opportunities for differentiation from Leqembi, Kisunla, and procognitive symptomatics in the early AD market.

QUESTIONS ANSWERED

  • How important is a therapy’s effect on cognition, function, or biomarker outcomes in neurologists’ selection of a therapy for early AD?
  • How do neurologists rate Leqembi, Kisunla, and procognitive symptomatics on their overall performance in the treatment of early AD and on key individual attributes?
  • Based on conjoint analysis and TPP simulation, what trade-offs among efficacy, safety, treatment duration, and other factors are neurologists willing to make when considering a hypothetical DMT for early AD?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
  • Analyze market scenarios for different target product profiles using the TPP Simulator

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 32 European neurologists fielded in December 2023

Key companies: AbbVie, Biogen, Eisai, Eli Lilly, Roche

Key drugs: Leqembi, Kisunla, donepezil, galantamine, Namzaric, rivastigmine patch

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east